The Cureus Journal of Medical Science is proud to introduce the Real-Time Adaptive Motion Management on Helical and Robotic Radiotherapy Platforms publishing competition.

Real-time adaptive motion management enhances the precision of dose delivery during radiotherapy. By continuously tracking and adapting to a target’s position, the uncertainty in the motion trajectory of the planned treatment volume (PTV) is reduced. This accuracy is vital for certain stereotactic body radiation therapy (SBRT) and stereotactic radiosurgery (SRS) techniques. Implementing real-time adaptive motion management can enable a reduction in internal target volumes (ITVs), further contributing to minimized dose to critical organs at risk (OAR).  

Individual authors may submit multiple articles. The current competition is restricted to case reports and case series (featuring a maximum of five cases) or technical reports illustrating real-time adaptive motion management on helical and robotic radiotherapy platforms. Eligible cases must include treatment with radiotherapy anywhere in the body, and describe the patient and their disease, the radiotherapy regimen (fractions, doses), clinical outcomes (toxicity and disease control) and practical considerations (treatment time).

Reports should focus on unique cases or case series that highlight a significant advantage of real-time adaptive motion management allowing clinicians to treat more effectively than treatments without real-time motion management. Technical reports focused on practical considerations with adaptive radiotherapy treatment planning, patient set up or other technical considerations are also welcomed. Competition submissions should clearly illustrate, with images and analyses, the advantages of real-time adaptive motion management on helical and robotic radiotherapy platforms.

In an effort to create broader awareness and understanding of related clinical experiences with such innovations, this program aims to share the resulting publications with the Cureus global community of radiation oncologists, clinical/medical oncologists, neurosurgeons, medical physicists and others who might benefit. To further encourage dissemination, published materials will also be designated Open Access and indexed with PubMed Central.

The winners of this competition will be determined by crowd-sourced ratings from the medical community using the Cureus Scholarly Impact Quotient™ (SIQ).

Program administration has been enabled through the financial support of Accuray, Inc. Article eligibility, editorial review, peer review, publication, and competition winner determination are strictly independent of the sponsor.